Your session is about to expire
← Back to Search
tDCS + CR for Mild Cognitive Impairment (PACt-MD Trial)
N/A
Waitlist Available
Led By Benoit H Mulsant, MD
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age > 60 (on day of randomization)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 4, 12, 24, 36, 48, 60 months after baseline
Awards & highlights
PACt-MD Trial Summary
This trial will compare the efficacy of a non-invasive brain stimulation combined with cognitive remediation versus a sham ("placebo") stimulation combined with a sham ("placebo") cognitive remediation in slowing down cognitive decline and preventing Alzheimer's Dementia in older persons with mild cognitive impairment or major depressive disorder with or without mild cognitive impairment.
Who is the study for?
This trial is for older adults over 60 who've had depression or a major depressive episode in the past decade. They must have mild cognitive impairment (MCI) or be stable with no recent substance abuse issues. A study partner is required, and participants need to understand English.Check my eligibility
What is being tested?
The study tests if brain stimulation (tDCS) combined with mental exercises (CR) can slow down memory loss and prevent Alzheimer's compared to placebo treatments, over a period of seven years.See study design
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site on the head, headache, fatigue, nausea, or itching under the electrodes used for tDCS.
PACt-MD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am over 60 years old.
PACt-MD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 4, 12, 24, 36, 48, 60 months after baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 4, 12, 24, 36, 48, 60 months after baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in cognitive scores over time
Secondary outcome measures
Percentage of subjects who remain free of MCI or dementia over time
PACt-MD Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: tDCS + CRExperimental Treatment1 Intervention
Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session.
Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. "Strategic monitoring and bridging discussions" promotes transfer of cognitive gains to everyday tasks.
During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).
Group II: sham tDCS + sham CRPlacebo Group1 Intervention
First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.
Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.
During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely).
Find a Location
Who is running the clinical trial?
Centre for Addiction and Mental HealthLead Sponsor
351 Previous Clinical Trials
80,991 Total Patients Enrolled
Brain CanadaOTHER
17 Previous Clinical Trials
5,589 Total Patients Enrolled
Applied Health Research CentreOTHER
22 Previous Clinical Trials
70,661 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger